Medistem has filed patent applications covering a broad spectrum of stem cell manipulations and applications that has come from both its basic scientific and targeted research. While many of these could be the basis for significant licensing and development opportunities, the Company has focused on the patents surrounding its endometrial regenerative cells (ERC) (Menstrual blood cellular populations, isolation and use thereof and Endometrial derived reparative/regenerative cells). These patent applications take a multidimensional approach at protecting the Company’s discoveries, covering 1) products generated from ERCs, 2) properties of the ERC products, and 3) application of the ERC products to specific disease indications.
Here’s a list of MediStem’s Patent Applications. Click on a link to learn more.
- Method for expansion of stem cells
- Compositions of placentally-derived stem cells for the treatment of cancer
- Transcatheter tumor immunoembolization
- Stem cell therapy for cardiac valvular dysfunction
- Allogeneic stem cell transplants in non-conditioned recipients
- Stem Cell Mediated Treg Activation/Expansion for Therapeutic Immune Modulation
- Compositions and methods of stem cell therapy for autism
- Stem cell therapy for weight loss
- Menstrual blood cellular populations, isolation, and use thereof
- Endometrial derived reparative/regenerative cells
- Stem cell therapy for autism
Method for expansion of stem cells
This application covers the composition of matter and use of a proprietary placenta derived product that is capable of expanding numerous types of stem cells both outside of the body ( ex vivo) and inside of the body (in vivo). This product is useful as a tissue culture reagent which allows for potent amplification of a patients own stem cells prior to reintroduction into the body. Another in vitro application is the utilization of this product as a research reagent which can be sold to various corporate and academic laboratories. More importantly, the ability of this product to expand stem cells in vivo implies that the major markets of hematopoiesis stimulation post chemotherapy, as well as cosmetic, rejuvenation, and antiaging markets may be addressed.
Compositions of placentally-derived stem cells for the treatment of cancer
This patent application covers preparations of a wide variety of stem cells and compositions useful for the treatment of cancer. The stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents.
Transcatheter tumor immunoembolization
Transcatheter chemoembolization is clinically used to treat patients with unresectable liver cancer. Our patent application teaches that by addition of a localized immune stimulus to the embolization mixture, we can use the cell death that occurs as a result of this procedure as an “endogenous vaccine” that will stimulate a systemic anti-tumor response. This is based on the fact that immunization in the liver usually results in the induction of a nonproductive immune response, but if appropriate immune stimulators are administered locally, an effective anticancer response will follow that is capable of removing tumor metastasis.
Stem cell therapy for cardiac valvular dysfunction
This patent application covers various mechanisms by which stem cell administration can inhibit the progression of valvular dysfunction, including mitral, aortic and semilunar valve regurgitation. The non-surgical regeneration of valve structures is highly desirable in patients that are not suitable to under highly invasive interventions due to age or other factors.
Allogeneic stem cell transplants in non-conditioned recipients
The current belief that immune suppression is needed for safety and efficacy of cord blood transplants is overcome by this patent application. The teachings of this patent, which have subsequently been published in the Journal of Translational Medicine, include methods of matching a donor with recipient so as to avoid immune mediated rejection, as well as selectively purifying the graft using clinically approved methods so as to allow for maximal stem cell activity without the need for immune suppression. This patent covers some of the technologies in the AngioStem platform.
Stem Cell Mediated Treg Activation/Expansion for Therapeutic Immune Modulation
This patent application provides ways of using stem cells, including adipose tissue mononuclear cells for immune regulation. The technologies in this patent may be used for providing therapeutic solutions to a wide variety of autoimmune diseases, as well as preventing post transplant rejection.
Compositions and methods of stem cell therapy for autism
This application covers the use of various pharmaceuticals that are currently approved for the mobilization of stem cells to treat autism. The invention is based on the finding that specific compounds such as G-CSF, induce stem cells to exit the bone marrow and enter the blood stream. These stem cells appear to have activity against autism, specifically they suppress various inflammatory reactions that are found in subsets of autistic patients. Additionally, in autism, patients often display a perfusion defect in various areas of the brain such as the temporal lobe. The mobilization of stem cells is used to increase the formation of new blood vessels so as to trigger increased circulation in patients that are identified.
Stem cell therapy for weight loss
Obesity is associated with numerous physiological abnormalities. In a subset of patients these abnormalities lead to altered metabolism so that even reduction in caloric intake has minimal effect on body mass. This patent application is based on clinical findings that various stem cell populations, especially derived from liposuction mononuclear cells, are capable of inducing weight-loss in subsets of patients.
Menstrual blood cellular populations, isolation, and use thereof
This patent application covers methods of using menstrual blood as a starting population of cells for isolation of numerous progenitor and stem cell subsets. The application includes various criteria for selection of cells that have specific uses. For example, in some embodiments of the invention cells are selected for high ability to make new blood vessels through isolation of populations having CD9 expression. In other embodiments the cells are selected for ability to differentiate into numerous other lineages, these populations are selected based on expression of c-kit. This application is aimed at covering the composition of matter for the starting cellular population found in the menstrual blood.
Endometrial derived reparative/regenerative cells
This patent application covers specific regenerative cell populations found in the menstrual blood and endometrium. The cell type itself is covered, as well as uses for stimulation of healing either through direct differentiation, anti-inflammatory activity, and/or stimulation of pre-existing endogenous progenitor cells. Numerous conditions may be treated with the cells described in the patent application, these range from autoimmune diseases, to neurodegenerative diseases, to cardiac diseases. This application is of particular interest since a unique cell population is disclosed.
Stem cell therapy for autism
This patent application covers the treatment of autism through delivery of a population of cells possessing anti-inflammatory effects together with a population capable of stimulating angiogenesis. The invention disclosed provides specific patient subsets that may benefit from administration of stem cells such as mesenchymal and CD34 cells.